A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at Berkeley, California and other locations
- Dates
- study startedcompletion around
- Principal Investigator
- by Hope S Rugo
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Hope S Rugo
Dr. Hope Rugo is a medical oncologist and hematologist specializing in breast cancer research and treatment. A Clinical Professor of Medicine, Dr. Rugo joined the Breast Care Center in 1999 after a decade of experience at UCSF in malignant hematology and bone marrow transplantation for a variety of diseases, including breast cancer.
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Eli Lilly and Company
- Links
- A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer (EMBER-4)
- ID
- NCT05514054
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- Expecting 6000 study participants
- Last Updated